{
    "Trade/Device Name(s)": [
        "CEDIA Heroin Metabolite (6-AM) Assay",
        "6-Acetylmorphine Immunoassay Test System"
    ],
    "Submitter Information": "Microgenics Corporation",
    "510(k) Number": "K173183",
    "Predicate Device Reference 510(k) Number(s)": [
        "k001178"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "September 28, 2017",
    "Summary Letter Received Date": "October 2, 2017",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "6-Acetylmorphine",
        "Heroin"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Clinical chemistry analyzers",
        "Beckman Coulter AU 680 Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay",
        "Recombinant DNA technology"
    ],
    "Methodologies": [
        "Immunoassay",
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for CEDIA Heroin Metabolite (6-AM) Assay, a homogeneous enzyme immunoassay for qualitative and semi-quantitative detection of heroin metabolite in urine.",
    "Indications for Use Summary": "Qualitative and/or semi-quantitative determination of heroin metabolite (6-Acetylmorphine) in human urine at a 10 ng/mL cutoff, intended for rapid screening in laboratory settings using clinical chemistry analyzers.",
    "fda_folder": "Toxicology"
}